PARIS & COPENHAGEN--(BUSINESS WIRE (http://www.businesswire.com/))-- Regulatory News: Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO), an innovative company specialized in the development of orphan oncology therapeutics, today announced that Company management is scheduled to present at the 18th Annual Rodman & Renshaw Global Investment Conference, being held September 11-13, 2016 at the Lotte New York Palace Hotel in New York, NY. During the presentation, Onxeo management will discuss recent clinical and operational milestones and its outlook for the future, including its clinical development plans for recently-acquired lead signal-interfering DNA product candidate AsiDNA™, updates on the ongoing Phase III ReLive trial of Livatag® and new steps in product development and commercialization of Beleodaq® including international expansion. Details of the presentation are as follows: · Date: Monday, September 12 · Time: 2:10 – 2:35 PM EDT · Location: Roswell (4th Floor) About Onxeo Onxeo is a leading developer of orphan oncology drugs. The Company is focused on developing innovative therapeutics for rare cancers, one of the fastest growing markets in the healthcare industry with high, unmet medical needs. Onxeo’s vision is to become a global leader and pioneer in oncology, with a focus on orphan or rare cancers, by developing advanced, effective, and safe therapeutics designed to improve the lives of patients. Onxeo’s comprehensive portfolio features a broad orphan oncology pipeline, with four independent programs in various stages of clinical development, including Onxeo’s first approved orphan oncology drug, Beleodaq®. The Company is headquartered in Paris, France and has approximately 50 employees. Onxeo is listed on Euronext in Paris, France (Ticker: ONXEO, ISIN Code: FR0010095596) and Nasdaq Copenhagen, Denmark (Ticker: ONXEO). Onxeo’s orphan oncology products are: · Livatag® (Doxorubicin Transdrug™): Currently being evaluated in a Phase III trial (ReLive) in patients with hepatocellular carcinoma (primary liver cancer); and in combination with other cancer agents in first-line HCC · Beleodaq® (belinostat): FDA-approved in the US in 2014 under the agency’s accelerated approval program as a second-line treatment for patients with peripheral T-cell lymphoma (PTCL) and currently marketed by Onxeo’s partner in the US, Spectrum Pharmaceuticals; belinostat in combination with other cancer agents is currently in development in first-line treatment for patients with PTCL (BelCHOP) and in other solid tumors · AsiDNA: The first-in-class siDNA (signal-interfering DNA) which has successfully undergone a proof-of-concept Phase I trial in metastatic melanoma · Validive® (Clonidine Lauriad®): Positive final results from a Phase II trial in head and neck cancer patients with severe oral mucositis In addition, Onxeo has successfully developed and registered two non-cancer products, which are currently being commercialized in the U.S. and Europe. Learn more by visiting www.onxeo.com (http://cts.businesswire.com/ct/CT?id=smartlink&url=http% 3 A%2F%2Fwww.onxeo.com&esheet=51415481&newsitemid=0&lan=en -US&anchor=www.onxeo.com&index=1&md5=bb08f9c6250f7c80ed9d4bb1ccd0d665). To receive our press releases and newsletters, please register on: http://www.onxeo.com/en/newsletter/ (http://cts.businesswire.com/ct/CT?id=sm a rtlink&url=http%3A%2F%2Fwww.onxeo.com%2Fen%2Fnewsletter%2F&esheet=51415481&newsi t emid=0&lan=en -US&anchor=http%3A%2F%2Fwww.onxeo.com%2Fen%2Fnewsletter%2F&index=2&md5=b8e70848e a 01e8a6af7891889814d5ac) Follow us on Twitter: @Onxeo_ Disclaimer This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward -looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2015 Reference Document filed with the AMF on April 29, 2016, which is available on the AMF website (http://www.amf -france.org (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww . amf-france.org&esheet=51415481&newsitemid=0&lan=en -US&anchor=http%3A%2F%2Fwww.amf -france.org&index=3&md5=edb3004bb38f2916957746b3c1480f2a)) or on the company’s website (www.onxeo.com (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2F w ww.onxeo.com&esheet=51415481&newsitemid=0&lan=en -US&anchor=www.onxeo.com&index=4&md5=19be51bb91d4e4d91384f924da94d7e8)). Contacts Onxeo S.A. Judith Greciet, CEO Nicolas Fellmann, CFO investors@onxeo.com +33 1 45 58 76 00 or Alize RP (France) Caroline Carmagnol / Florence Portejoie onxeo@alizerp.com +33 6 64 18 99 59 / +33 6 47 38 90 04 or The Ruth Group (U.S.) Kirsten Thomas / Lee Roth kthomas@theruthgroup.com / lroth@theruthgroup.com +1 508 280 6592 / +1 646 536 7012
Onxeo to Present at the 18th Annual Rodman and Renshaw
Top 10 Most Recent News Articles
Revolutionizing Textiles: Touchscreen Garments Emerge
Picture a world where your shirt does more than just cover your back. Bingo, folks—smart textiles have taken center stage with groundbreaking technology that melds touchscreens with fabric, and the brains behind it hail from the National University of Singapore (NUS). It's not just about slapping a few LEDs onto a vest. We're talking about clothing that can display...
Continue Reading
OTconnect on Apple Watch: A New Fitness Era Dawns
What’s Orangetheory Up To Now? Ah, fitness gadgets, where everyone’s seemingly got a scheme brewing. This time it's Orangetheory (OTF), turning your Apple Watch into your new best gym buddy. October 22, 2026, marks the launch of OTconnect for Apple Watch, offering a slick way for enthusiasts to tune into their own sweat metrics. If you’re already an Apple Watch...
Continue Reading
LEDC and Crosson Lead the Charge in Community Finance
Recognizing Game-Changers in Community Development Finance In the financial landscape, it's not always about the big tickers and glitzy IPOs. Sometimes, it's the intrepid ground-level players who make the real difference. That's exactly what happened when the Opportunity Finance Network (OFN) held its 42nd annual conference in New Orleans, honoring standouts in the realm...
Continue Reading
Unicycive's Stock Plunge: Fraud Suit and FDA Hurdles
Unicycive's Tumultuous Journey Lately, it's been a rocky road for Unicycive Therapeutics, Inc., with their stock free-falling 39.1% in the span of a heartbeat on June 30, 2026. What sparked this nosedive? The FDA kicked back their revised New Drug Application for a kidney disease treatment yet again, spotlighting old manufacturing issues never nipped in the bud. Talk...
Continue Reading
Navigating Car Accidents in Connecticut: Essential Steps
Understanding the Immediate Chaos Post-Accident Alright, picture this: you've just been in a car accident in Connecticut. Your heart's pounding, and the scene's full of chaos. But here's the kicker - the actions you take now are crucial. It's easy to focus on the crumpled metal of your vehicle, but there's more at stake here. The decisions you make in these moments can...
Continue Reading
Texas A&M-San Antonio Opens $55M Health Hub
Building Blocks for Future Health Experts They say money talks, and down in San Antonio, it just shouted loud and clear. Texas A&M University-San Antonio sliced the ribbon on a $55 million Public Health and Education building, a step that isn’t just about bricks and mortar, but life-saving insights and hands-on training that'll ripple across South Texas. This isn’t...
Continue Reading
California Waste Solutions: Investing in Vietnam's Future
Some folks see trash. David Duong sees hope—and dollar signs. This man ain't just talking trash collection; he's flipping waste into opportunity and, more importantly, into core community building in Vietnam. Over at Vietnam Waste Solutions, a subsidiary of California Waste Solutions, they're blending environmental breakthroughs with good old-fashioned community values....
Continue Reading
Oakworth Capital's Strategic Gains: A Deep Dive
Oakworth Capital's Big Moves This Quarter Diving right into the Alabama-based Oakworth Capital's latest numbers, they did not pull any punches with a hefty 19% bump in net income. Now, in a world where banking can sometimes feel like riding a porcupine, Oakworth's ability to rise above speaks volumes. They clocked in at $17.2 million net income for the year-to-date period...
Continue Reading
Xona's $250M Raise: GPS Transformation Sparks Debate
The Satellite Race Heats Up: Xona's Ambitious Leap Hold onto your hats, folks, because Xona's making headlines with a $250 million infusion. This ain't just pocket change—it's part of a rocket-fueled mission to upend the GPS landscape. Imagine a world where GPS is 100 times stronger. That's the pitch, and folks, it's got the market buzzing. Valuation Rocketing: Investor...
Continue Reading
Low GWP Refrigerants: Potential $13B Market by 2031
Refrigerants: They're Hot in More Ways Than One Who would've thought refrigerants could be such a big deal? But here we are. The low global warming potential (GWP) refrigerants market is heating up, projected to jump from $8.17 billion in 2026 to a whopping $13.06 billion by 2031. That's a solid 9.8% CAGR if you're keeping score. The drivers? Well, we’ve got...
Continue ReadingTop 5 Most Recently Viewed Articles
Nuvini Group Limited: Key Developments and Future Vision
Key Developments and Future Outlook for Nuvini Group Limited Nuvini Group Limited (NASDAQ: NVNI), a major player in the private B2B SaaS sector in Latin America, recently shared insights from their Founder and CEO, Pierre Schurmann. The company is in a transformative phase as it explores innovative strategies to enhance its portfolio, which has become increasingly...
Continue Reading
Key Consumer Announcement Highlights That You Shouldn't Miss
Consumer News Recap: Highlights You Should Check Out In a world where consumer trends and announcements flow ceaselessly, it's essential to stay updated. This week brings us an exciting selection of noteworthy releases across various sectors, from beloved brands reintroducing classic items to innovative new offerings. Let's dive into a recap of the major stories that have...
Continue Reading
Nescafé Fusion Empowers Food Service with Custom Coffee Offerings
Nescafé Fusion Empowers Food Service with Custom Coffee Offerings Nescafé Professional has introduced the Nescafé Fusion system, a revolutionary range of coffee machines designed for food service providers who seek to deliver a tailored coffee experience. This system presents an extensive collection of beverage choices that cater to every palate, from refreshing iced...
Continue Reading
Investec Adjusts Nestle India's Stock Target Amid Market Concerns
Investec Lowers Price Target for Nestle India Shares Recently, Investec made headlines by revising its price target for Nestle India Ltd (NEST:IN) shares. The new target of INR2,425.00 represents a reduction from the prior target of INR2,649.00. Despite this shift, Investec maintained a Hold rating on the stock. This decision follows a disappointing financial quarter for...
Continue Reading
Gianmaria Delzanno Joins Cadre Holdings Board Enhancing Leadership
Gianmaria Delzanno Joins the Board of Directors at Cadre Holdings Cadre Holdings, Inc. (NYSE: CDRE), recognized globally for its dedication to safety equipment and services catering to law enforcement and emergency responders, has announced a significant leadership change. The company has welcomed Gianmaria Delzanno to its Board of Directors, marking a pivotal moment for...
Continue Reading